Home / Pharmaceuticals / Opioid Induced Constipation (OIC) Drugs Market By Drug Type (Methylnaltrexone Bromide, Lubiprostone, Naloxegol, Naldemedine, Docusate Sodium, Others), By Prescription Type (Prescribed, Over The Counter) - Growth, Future Prospects And Competitive Analysis, 2018 – 2026

Opioid Induced Constipation (OIC) Drugs Market By Drug Type (Methylnaltrexone Bromide, Lubiprostone, Naloxegol, Naldemedine, Docusate Sodium, Others), By Prescription Type (Prescribed, Over The Counter) - Growth, Future Prospects And Competitive Analysis, 2018 – 2026

Published: Feb 2018 | Report Code: 57737-02-18

The mechanism of action of opioid analgesics through binding to the mu, delta and kappa receptors present in the brain by crossing the blood brain barrier and giving the desired analgesic effect to treat non-cancer pain. In addition, the opioids bind to the mu receptors present in the gastrointestinal tract, which result in contraction of the smooth muscles and alter the peristaltic movement causing constipation. Usually the patients opt for over the counter osmotic laxatives and stimulant cathartics, which have been beneficial in providing relief from constipation in patients taking opioid analgesics for 3-4 weeks. In patients seeking palliative care, doctors prescribe mu-receptor antagonists and prostaglandin derivatives to cure opioid induced constipation.

The drug types considered for the scope of the report are segmented as methylnaltrexone bromide, lubiprostone, naloxegol, naldemedine, docusate sodium and others. The prescription types segment includes prescribed and over the counter drugs. CAGR and market size is given for the above-mentioned segments.

The geography segment for opioid induced constipation drugs market includes major geographical regions, which is presented as follows:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

The market size and CAGR are given for the geographical regions along with their major countries in the scope of the report.

The company profiles section provides useful information such as product portfolio exhibiting the diverse range of over the counter drugs available such as osmotic laxatives, stimulant cathartics, herbal extracts, and prescribed drugs used to relieve constipation induced due to the use of opioid analgesics. Recent developments give brief elucidation of the latest mergers and acquisitions, and strategic events between key players. Competitive analysis presented in this report gives idea regarding the competitive environment prevalent in the opioid induced constipation drugs market. This report is an important market assessment tool, which helps in understanding the latest market trend existing in the opioid induced constipation drugs market by supplementing the market size and CAGR for drug type and prescription type. The key players pioneering in the opioid induced constipation drugs market are AstraZeneca, Cubist Pharmaceuticals (Adolor Corporation), Daiichi Sankyo Co. Ltd., Ironwood Pharmaceuticals, Inc., Pfizer, Inc., Progenics Pharmaceuticals, Inc., Salix Pharmaceuticals Ltd., Shionogo & Co Ltd., Sucampo Pharmaceuticals, Inc. and Synergy Pharmaceuticals, Inc.

Opioid Induced Constipation (OIC) Drugs Market

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Phase III-Expert Panel Review
1.3.4. Assumptions

Chapter 2. Executive Summary
2.1. Global Opioid Induced Constipation Drugs Market Portraiture
2.2. Global Opioid Induced Constipation Drugs Market, by Drug Type, 2017 (US$ Mn)
2.3. Global Opioid Induced Constipation Drugs Market, by Prescription Type, 2017 (US$ Mn)
2.4. Global Opioid Induced Constipation Drugs Market, by Geography, 2017 (US$ Mn)

Chapter 3. Opioid Induced Constipation Drugs Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Top 3 Countries: Global Opioid Induced Constipation Drugs Market, 2016-2026 (US$ Mn)
3.7. Competitive Landscape: Global Opioid Induced Constipation Drugs Market, by Key Players, 2016-2026 (US$ Mn)

Chapter 4. Global Opioid Induced Constipation Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
4.1. Overview
4.1.1. Competitive Analysis: Global Opioid Induced Constipation Drugs Market, by Drug Type, 2017 Vs. 2026 (Value %)
4.2. Methylnaltrexone Bromide
4.3. Lubiprostone
4.4. Naloxegol
4.5. Naldemedine
4.6. Docusate Sodium
4.7. Others
4.8. Pipeline Analysis
4.8.1. Phase III Drugs (Estimation till 2026 (US$ Mn))
4.8.1.1. Elobixibat
4.8.2. Phase II Drugs (Qualitative Information)
4.8.2.1. Dolcanatide

Chapter 5. Global Opioid Induced Constipation Drugs Market, by Prescription Type, 2016 – 2026 (US$ Mn)
5.1. Overview
5.1.1. Competitive Analysis: Global Opioid Induced Constipation Drugs Market, by Prescription Type, 2017 Vs. 2026 (Value %)
5.2. Prescribed
5.2.1. Branded
5.2.2. Generic
5.3. Over the Counter (OTC)

Chapter 6. Global Opioid Induced Constipation Drugs Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.2. North America Opioid Induced Constipation Drugs Market Analysis, 2016 – 2026 (US$ Mn)
6.2.1. North America Opioid Induced Constipation Drugs Market, by Country, 2016 – 2026 (US$ Mn)
6.2.1.1. U.S.
6.2.1.2. Canada
6.3. Europe Opioid Induced Constipation Drugs Market Analysis, 2016 – 2026 (US$ Mn)
6.3.1. Europe Opioid Induced Constipation Drugs Market, by Country, 2016 – 2026 (US$ Mn)
6.3.1.1. U.K.
6.3.1.2. Germany
6.3.1.3. Rest of Europe
6.4. Asia Pacific Opioid Induced Constipation Drugs Market Analysis, 2016 – 2026 (US$ Mn)
6.4.1. Asia Pacific Opioid Induced Constipation Drugs Market, by Country, 2016 – 2026 (US$ Mn)
6.4.1.1. China
6.4.1.2. Japan
6.4.1.3. Rest of APAC
6.5. Latin America Opioid Induced Constipation Drugs Market Analysis, 2016 – 2026 (US$ Mn)
6.5.1. Latin America Opioid Induced Constipation Drugs Market, by Country, 2016 – 2026 (US$ Mn)
6.5.1.1. Brazil
6.5.1.2. Mexico
6.5.1.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Opioid Induced Constipation Drugs Market Analysis, 2016 – 2026 (US$ Mn)
6.6.1. MEA Opioid Induced Constipation Drugs Market, by Region, 2016 – 2026 (US$ Mn)
6.6.1.1. GCC
6.6.1.2. Rest of MEA

Chapter 7. Company Profiles
7.1. AstraZeneca plc
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Cubist Pharmaceuticals (Adolor Corporation)
7.3. Daiichi Sankyo Co., Ltd.
7.4. Ironwood Pharmaceuticals, Inc.
7.5. Pfizer, Inc.
7.6. Progenics Pharmaceuticals, Inc.
7.7. Salix Pharmaceuticals Ltd.
7.8. Shionogo & Co., Ltd.
7.9. Sucampo Pharmaceuticals, Inc.
7.10. Synergy Pharmaceuticals, Inc.

List Of Table :

TABLE 1 Global Opioid Induced Constipation Drugs Market Portraiture
TABLE 2 Global Opioid Induced Constipation Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
TABLE 3 Global Opioid Induced Constipation Drugs Market, by Prescription Type, 2016 – 2026 (US$ Mn)
TABLE 4 Global Prescribed Drugs Market for Opioid Induced Constipation, by Prescription Type, 2016 – 2026 (US$ Mn)
TABLE 5 Global Opioid Induced Constipation Drugs Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 6 North America Opioid Induced Constipation Drugs Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 7 Europe Opioid Induced Constipation Drugs Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 8 Asia Pacific Opioid Induced Constipation Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Latin America Opioid Induced Constipation Drugs Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 10 Middle East and Africa Opioid Induced Constipation Drugs Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 11 AstraZeneca plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 12 Cubist Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 13 Daiichi Sankyo Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 14 Ironwood Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 Progenics Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 Salix Pharmaceuticals Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 Shionogo & Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Sucampo Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 Synergy Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

List Of Figures :

FIG. 1 Opioid Induced Constipation Drugs: Market Segmentation
FIG. 2 Global Opioid Induced Constipation Drugs Market Share, by Drug Type, 2017 (US$ Mn)
FIG. 3 Global Opioid Induced Constipation Drugs Market, by Prescription Type, 2017 (US$ Mn)
FIG. 4 Global Opioid Induced Constipation Drugs Market Share, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition, by Geography, 2017
FIG. 6 Top 3 Countries: Global Opioid Induced Constipation Drugs Market, 2016-2026 (US$ Mn)
FIG. 7 Market Competition Landscape, by Key Players, 2017
FIG. 8 Competitive Analysis: Global Opioid Induced Constipation Drugs Market, by Drug Type, 2017 Vs. 2026 (Value %)
FIG. 9 Global Methylnaltrexone Bromide Drug Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 10 Global Lubiprostone Drug Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 11 Global Naloxegol Drug Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 12 Global Naldemedine Drug Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 13 Global Docusate Sodium Drug Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 14 Global Other Drugs Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 15 Competitive Analysis: Global Opioid Induced Constipation Drugs Market, by Prescription Type, 2017 Vs. 2026 (Value %)
FIG. 16 Global Branded Drugs Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 17 Global Generic Drugs Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 18 Global Over the Counter Drugs Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 19 U.S. Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 20 Canada Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 21 U.K. Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 22 Germany Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 23 Rest of Europe Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 24 China Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 25 Japan Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 26 Rest of Asia Pacific Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 27 Brazil Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 28 Mexico Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 29 Rest of Latin America Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 30 GCC Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 31 Rest of Middle East and Africa Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)

Based on drug type, the opioid induced constipation drugs market is categorized into:

  • Methylnaltrexone Bromide
  • Lubiprostone
  • Naloxegol
  • Naldemedine
  • Docusate Sodium
  • Others

Opioid Induced Constipation (OIC) Drugs Market

According to the World Health Organization 2015 report, there has been a significant increase in the number of opioid analgesics prescribed for non-cancer pain in the last decade. Each year, approximately 40 million people are receiving palliative care throughout the globe to reduce pain intensity and improve patients’ quality of life. The factors responsible for the growth of non-cancer pain are Kellgren Lawrence grade 3 osteoarthritis, neuropathic pain, rheumatoid arthritis and severe fibromyalgia. As per the research citing of the Center for Disease Control and Prevention (2015), more than 40% of the patients receiving opioid analgesics suffer with constipation and other gastrointestinal complications. Currently, drugs such as osmotic laxatives, stimulant cathartics dominate the market as the patients usually prefer over the counter products to get relief from constipation. Physicians usually prescribe OTC laxatives along with opioid analgesics on account of their safety and less gastrointestinal complications. Naloxegol will register a significant growth during the forecast period from 2018 to 2026 on account of rising prevalence of non-cancer pain diseases such as osteoarthritis, fibromyalgia etc. Moreover, enhanced drug efficacy and less drug related adverse events such as diarrhea and bloating in comparison to other mu receptor antagonists (e.g. methylnaltrexone bromide) drive naloxegol’s market demand. Recently naldemedine manufactured by Shionogi, Inc. has received FDA approval for the treatment of OIC and will register excellent growth during the forecast period. The key players pioneering in the opioid induced constipation drugs market are AstraZeneca, Cubist Pharmaceuticals (Adolor Corporation), Daiichi Sankyo Co. Ltd., Ironwood Pharmaceuticals, Inc., Pfizer, Inc., Progenics Pharmaceuticals, Inc., Salix Pharmaceuticals Ltd., Shionogo & Co Ltd., Sucampo Pharmaceuticals, Inc. and Synergy Pharmaceuticals, Inc.

For the purpose of this study, the global opioid induced constipation drugs market is categorized into the following regional and country specific markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Opioid Induced Constipation (OIC) Drugs Market

North America currently leads the opioid induced constipation drugs market due to increasing number of patients suffering with non-cancer pain and rising public health awareness resulting in early diagnosis and treatment for osteoarthritis and rheumatoid arthritis. European opioid induced constipation drugs market is driven by increasing number of patients seeking palliative care in rehabilitation centers and rising geriatric population suffering with non-cancer pain. Asia Pacific is set to register significant growth in opioids induced constipation drugs market on account of huge population base suffering with chronic diseases such as rheumatoid arthritis and fibromyalgia associated with strenuous working conditions. Rising use of opioids due to easy availability and poor regulation drives the Asia Pacific opioids induced constipation drugs market.

Based on prescription type, the opioid induced constipation drugs market is categorized into:

  • Prescribed
    • Branded
    • Generic
  • Over the Counter

Opioid Induced Constipation (OIC) Drugs Market

The American Society of Addiction Medicine (2016 facts) states that approximately 2 million U.S. citizens were having a substance use disorder related to prescribed opioid analgesics. The World Health Organization 2015, report mentions that 15.3 million people throughout the globe are suffering with opioid use disorder resulting in severe constipation. In the present scenario, prescribed drugs are dominating the market on account of increasing number of patients showing resistance to over the counter laxatives and cathartics. Moreover opioid analgesics binds to the mu receptors of gastrointestinal tract causing severe contraction of smooth muscles, altering the peristaltic activity of the gut motility, thus leading to chronic constipation. Physicians usually prescribe branded drugs such as methylnaltrexone bromide and naloxegol (mu-receptor antagonists) and prostaglandin derivatives such as lubiprostone to gain immediate relief from constipation by increasing fluid retention and stool softening. Over the counter (OTC) osmotic laxatives and stimulant cathartics are the drugs of first choice by the patients to treat constipation. OTC products have shown good results in patients taking opioid analgesics for less than 4 weeks.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients